Your browser doesn't support javascript.
loading
Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study.
Gogas, H; Dréno, B; Larkin, J; Demidov, L; Stroyakovskiy, D; Eroglu, Z; Francesco Ferrucci, P; Pigozzo, J; Rutkowski, P; Mackiewicz, J; Rooney, I; Voulgari, A; Troutman, S; Pitcher, B; Guo, Y; Yan, Y; Castro, M; Mulla, S; Flaherty, K; Arance, A.
Afiliação
  • Gogas H; First Department of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece. Electronic address: helgogas@gmail.com.
  • Dréno B; Dermatology Department, CHU Nantes, CIC 1413, CRCINA, University Nantes, Nantes, France.
  • Larkin J; Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Demidov L; N.N. Blokhin Russian Cancer Research Center, Ministry of Health, Moscow, Russia.
  • Stroyakovskiy D; Moscow City Oncology Hospital #62 of Moscow Healthcare Department, Moscow Oblast, Russia.
  • Eroglu Z; Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA.
  • Francesco Ferrucci P; European Institute of Oncology - IRCCS, Milan, Italy.
  • Pigozzo J; Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
  • Rutkowski P; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Mackiewicz J; Department of Medical and Experimental Oncology, Poznan University of Medical Sciences, and Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Center, Poznan, Poland.
  • Rooney I; Genentech, Inc., South San Francisco, USA.
  • Voulgari A; Roche Products Ltd, Welwyn Garden City, UK.
  • Troutman S; Genentech, Inc., South San Francisco, USA.
  • Pitcher B; Hoffmann-La Roche Ltd., Mississauga, Canada.
  • Guo Y; Genentech, Inc., South San Francisco, USA.
  • Yan Y; Genentech, Inc., South San Francisco, USA.
  • Castro M; Genentech, Inc., South San Francisco, USA.
  • Mulla S; Hoffmann-La Roche Ltd., Mississauga, Canada.
  • Flaherty K; Massachusetts General Hospital Cancer Center, Boston, USA.
  • Arance A; Department of Medical Oncology and IDIBAPS, Hospital Clínic Barcelona, Barcelona, Spain.
Ann Oncol ; 32(3): 384-394, 2021 03.
Article em En | MEDLINE | ID: mdl-33309774
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas B-raf / Melanoma Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas B-raf / Melanoma Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article